A Phase I Study: PET Imaging of Cancer Patients Using [18F] 4-L-Fluoroglutamine (2S,4R)

Inclusion Criteria:

• Patients with history of histologically-confirmed solid malignancy and/or lymphoma (histology confirmed by MSKCC Department of Pathology.) Disease measurable orevaluable as defined by RECIST 1.1 or other tumor response criteria from an MSKCCIRB-approved clinical research protocol. NOTE: Study patients do not need to beparticipating in an MSKCC approved clinical trial prior to study recruitment.

• Age between 21-90

• Negative serum pregnancy test for female patients of childbearing age and potential (as defined by MSKCC Standards & Guidelines), from assays obtained <2 weeks prior tostudy enrollment. Patients will be advised against having unprotected sexualintercourse from the time of the negative serum pregnancy test until aftercompleting their participation in the study.

Exclusion Criteria:

• Inability or refusal to have at least one peripheral intravenous line forintravenous access (as applicable to the day of [18F] 4-L-Fluoroglutamine (2S,4R)injection and blood draws.)

• Breast-feeding

• Refusal or inability to tolerate the scanning procedure (e.g., due toclaustrophobia)

• Hepatic: from assays obtained <2 weeks prior to study enrollment For each patient,the upper limit of normal (ULN) value for a particular assay will be defined by thenormal reference values of the laboratory that performed the assay.

• Bilirubin > 1.5 x (ULN)

• AST/ALT >2.5 x ULN

• Albumin < 3 g/dl

• GGT > 2.5 x ULN IF Alkaline phosphatase > 2.5 x ULN.

• Renal: Creatinine >1.5 x ULN or creatinine clearance < 60 mL/min, from assaysobtained <2 weeks prior to study enrollment

• Acute major illness (e.g., unstable cardiovascular condition, etc.)